Buspirone Therapy in Anxious Elderly Patients

Böhm, Claus; Robinson, Donald S.; Gammans, Richard E.; Shrotriya, Rajesh C.; Alms, Donald R.; Leroy, Annick; Placchi, M.

doi:10.1097/00004714-199006001-00010

Cited by 54 publications

(23 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As has been demonstrated in previous research with buspirone in geriatric populations, few sideeffects were reported (Robinson et d., 1988;Bohm et al, 1990). The side-effects were generally mild, and no subject was forced to withdraw due to sideeffects of buspirone.…”

Section: Open Label Continuation Phasesupporting

confidence: 60%

A trial of buspirone for the control of disruptive behaviors in community‐dwelling patients with dementia

Levy

Burgio

Sweet

et al. 1994

Int J Geriat Psychiatry

View full text Add to dashboard Cite

SUMMARYWe report the results of a pilot study examining the dose-response of buspirone for the treatment of agitated and disruptive behaviors in dementia patients. Patients were identified by physician referral, chart review and caregiver response to newspaper advertisements. All subjects met NINCDS-ADRDA criteria for probable Alzheimer's disease. Twenty subjects were entered into the study, 12 completed the protocol. After a washout period, all subjects received 1 week of placebo followed by approximately 2 weeks each of buspirone 15 mg, 30 mg, 45 mg and 60 mg daily. The primary outcome measure was the total score on Reisberg's Behavioral Pathology in Alzheimer's Disease Rating Scale (BEHAVE-AD), which was administered at baseline, the end of the placebo phase and at the end of each dosage interval. Significant improvement in the mean score was seen at a daily dosage of 30 mg (p < 0.05 vs placebo). Significant improvement was also seen on the delusion, aggression and anxiety subscales of the BEHAVE-AD. Few side-effects were noted. These data suggest that the optimal starting dosage of buspirone for the treatment of behavioral pathology in dementia patients is 30 mg daily. Individual patients may have their best response at dosages ranging from 15 to 60 mg daily. Confirmation of these findings requires a double-blind, placebo-controlled clinical trail.KEY worm-Dementia, buspirone, agitation.Disruptive, agitated and aggressive behaviors are common in patients with dementia (Teri etal., 1988;Rubin et a/., 1988;Reisberg et al., 1987). These behaviors are a major source of caregiver stress and frequently lead to nursing home placement (Ferris et al., 1985). Despite the growing acceptance and utilization of non-pharmacologic interventions and increasing institutional regulations limiting the use of pharmacotherapy, psychotropic drug ther-

show abstract

Section: Open Label Continuation Phasesupporting

confidence: 60%

A trial of buspirone for the control of disruptive behaviors in community‐dwelling patients with dementia

Levy

Burgio

Sweet

et al. 1994

Int J Geriat Psychiatry

View full text Add to dashboard Cite

show abstract

“…123,124 Unlike other anxiolytics and like antidepressants, it takes about 2 weeks to become effective, so would be indicated for the management of severe, chronic GAD rather than acute anxiety states. However, longer-term studies of its effectiveness are still needed.…”

Section: Pharmacologicalmentioning

confidence: 99%

Anxiety disorders in older people

Lindesay

Stewart

Bisla

2012

Rev. Clin. Gerontol.

View full text Add to dashboard Cite

SummaryThis article reviews the research into anxiety disorders in adults aged 65 years and older that has been published over the past ten years. The topics covered include: the construct of anxiety and its disorders in this age group; epidemiology, including prevalence, incidence, course, outlook, and risk factors; assessment scales; co-morbidity and differential diagnosis (depression, dementia, physical illness); and management, both pharmacological and non-pharmacological. There has been a significant improvement in our understanding of these disorders in older adults over this period, but evidence to support their treatment and prevention is still quite sparse.

show abstract

“…In a study involving 40 elderly patients with anxiety in primary care, buspirone was effective (as measured by the HRSA and Clinical Global Impression scale) and well tolerated, with an adverse effect profile similar to that of placebo (Bohm 1990). Again, however, there is no direct evidence to support its use for anxiety in dementia.…”

Section: Buspironementioning

confidence: 98%

Anxiety: a hidden element in dementia

Badrakalimuthu¹,

Tarbuck²

2012

Adv. psychiatr. treat

View full text Add to dashboard Cite

SummaryAnxiety has reported prevalence rates between 38 and 72% among people with dementia. It has a negative impact on cognitive impairment and is associated with agitation and poor quality of life. The presence of excessive anxiety can be difficult to establish in people with dementia, especially when expressive or receptive speech is impaired. Unfortunately, there is a lack of research on the treatment of anxiety in dementia, and also on the wider issue of the management of anxiety disorders in old age. We explore the prevalence, presentation and diagnosis of anxiety in dementia and discuss the therapeutic options available.

show abstract

Buspirone Therapy in Anxious Elderly Patients

Cited by 54 publications

References 0 publications

A trial of buspirone for the control of disruptive behaviors in community‐dwelling patients with dementia

A trial of buspirone for the control of disruptive behaviors in community‐dwelling patients with dementia

Anxiety disorders in older people

Anxiety: a hidden element in dementia

Contact Info

Product

Resources

About